Evidence map›Paper›PMID 35416117›Full record

ArticleBioengineered2022

Discoidin domain receptor 1a (DDR1a) confers 5-fluorouracil cytotoxicity in LoVo cell via PI3K/AKT/Bcl-2 pathway.

Bin Xiong, Fei-Xue Song, Hui-Ling Chen, Xiao-Juan Wang, Zheng-Xu Jin, Ti-Yun Han, Yi Li, De-Kui Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Role of DDR1 in Regulating MMPs in External Root Resorption.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Bin XiongDepartment of Oncology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China.
Fei-Xue SongDepartment of Oncology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China.
Hui-Ling ChenThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
Xiao-Juan WangThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
Zheng-Xu JinThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
Ti-Yun HanLaboratory of Digestive Disease, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China.
Yi LiSchool/Hospital of Stomatology Lanzhou University, Lanzhou, Gansu, China.
De-Kui ZhangDepartment of Gastroenterology, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China.ORCID 0000-0002-4883-8713
Lanzhou University Second Hospital · CNLanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-Fluorouracil (5-FU) is a common chemotherapy drug for patients with advanced colorectal cancer; however, many patients develop resistance to 5-FU and suffer from treatment failure. Discoidin domain receptor 1 (DDR1) is upregulated in multiple cancers and positively associated with chemoresistance. We explored the effect of DDR1a on the cytotoxicity induced by 5-FU in LoVo cells and the underlying mechanism. Therefore, DDR1a overexpression (DDR1a

Indexed as

Colorectal NeoplasmsPhosphatidylinositol 3-KinasesApoptosisCell Line, TumorDiscoidin Domain Receptor 1Discoidin Domain ReceptorsDrug Resistance, NeoplasmFluorouracilHumansProto-Oncogene Proteins c-aktDDR1 protein, humanDiscoidin Domain Receptor 1Discoidin Domain ReceptorsFluorouracilPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt5-fluorouracilcolorectal cancercytotoxicityDiscoidin domain receptor 1aproliferation

Identifiers

PMID35416117
PMCPMC9161994
OpenAlexW4223505086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.